Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 18:14:1203471.
doi: 10.3389/fimmu.2023.1203471. eCollection 2023.

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma

Jennifer E Agrusa  1 , Emily R Egress  2 , Eric J Lowe  2   3
Affiliations
Review

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma

Jennifer E Agrusa et al. Front Immunol. .

Abstract

Anaplastic large cell lymphoma (ALCL) is the most common type of mature T-cell non-Hodgkin lymphoma in children/adolescents. ALCL is characterized by expression of CD30 in the neoplastic lymphoid cells with frequent expression of anaplastic lymphoma kinase (ALK), especially within the pediatric population. Despite multiple efforts to optimize the use of conventional chemotherapy, outcomes in children, adolescents, and adults with ALCL remain suboptimal. Thus, there is a need to improve survival for those with high-risk disease and decrease therapy exposures and toxicities for those with low-risk disease. Targeted therapies, such as the anti-CD30 antibody-drug conjugate, brentuximab vedotin, are new important therapeutic options. Phase I and II studies in adults with relapsed/refractory CD30+ lymphomas, including ALCL, demonstrated the safety and efficacy of brentuximab vedotin, leading to FDA approval for relapsed/refractory ALCL in adults and successful incorporation into frontline therapies. Clinical trials in the pediatric population demonstrated similar results in those with relapsed/refractory ALCL. Incorporation of brentuximab vedotin into upfront therapy for children and adolescents with ALCL showed that this novel combination therapy has clinical advantages in comparison to conventional agents alone. Brentuximab vedotin is well-tolerated in both the pediatric and adult populations, even when used in combination with conventional agents. Brentuximab vedotin is an ideal agent to treat ALCL with excellent targeted activity and limited toxicity. Future studies are needed to identify how brentuximab vedotin should be utilized when combined with immunotherapy or other targeted agents (e.g., ALK inhibitors) in both the upfront and relapsed/refractory setting.

Keywords: ALCL; Brentuximab vedotin; CD30; anaplastic large cell lymphoma; non-Hodgkin lymphoma; pediatric.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Brentuximab Vedotin’s Mechanism of Action. MMAE: monomethyl auristatin E. Created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Delsol G, Al Saati T, Gatter KC, Gerdes J, Schwarting R, Caveriviere P, et al. . Coexpression of epithelial membrane antigen (EMA), ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. diagnostic value in so-called malignant histiocytosis. Am J Pathol (1988) 130(1):59–70. - PMC - PubMed
    1. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. . The expression of the hodgkin's disease associated antigen ki-1 in reactive and neoplastic lymphoid tissue: evidence that reed-sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood (1985) 66(4):848–58. doi: 10.1182/blood.V66.4.848.848 - DOI - PubMed
    1. Alessandri AJ, Pritchard SL, Schultz KR, Massing BG. A population-based study of pediatric anaplastic large cell lymphoma. Cancer (2002) 94(6):1830–5. doi: 10.1002/cncr.10396 - DOI - PubMed
    1. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the national cancer data base from 1998 to 2011. Am J Hematol (2015) 90(9):790–5. doi: 10.1002/ajh.24086 - DOI - PubMed
    1. Wright D, McKeever P, Carter R. Childhood non-Hodgkin lymphomas in the united kingdom: findings from the UK children's cancer study group. J Clin Pathol (1997) 50(2):128–34. doi: 10.1136/jcp.50.2.128 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources